Zhejiang Xinguang Pharmaceutical Co Ltd (300519) - Total Assets
Based on the latest financial reports, Zhejiang Xinguang Pharmaceutical Co Ltd (300519) holds total assets worth CN¥893.41 Million CNY (≈ $130.73 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300519 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Xinguang Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Zhejiang Xinguang Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Zhejiang Xinguang Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Zhejiang Xinguang Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Xinguang Pharmaceutical Co Ltd's total assets of CN¥893.41 Million consist of 85.2% current assets and 14.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 55.3% |
| Accounts Receivable | CN¥12.62 Million | 1.4% |
| Inventory | CN¥69.34 Million | 7.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥7.88 Million | 0.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Zhejiang Xinguang Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zhejiang Xinguang Pharmaceutical Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Xinguang Pharmaceutical Co Ltd's current assets represent 85.2% of total assets in 2024, an increase from 54.4% in 2011.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2024, up from 28.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 7.6% of total assets.
Zhejiang Xinguang Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Xinguang Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Zhejiang Xinguang Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.41 | 11.50 | 14.20 |
| Quick Ratio | 12.35 | 10.56 | 13.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥710.41 Million | CN¥688.12 Million | CN¥690.58 Million |
Zhejiang Xinguang Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Xinguang Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.99 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | -2.2% |
| Total Assets | CN¥909.78 Million |
| Market Capitalization | $290.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Xinguang Pharmaceutical Co Ltd's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Xinguang Pharmaceutical Co Ltd's assets decreased by 2.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥909.78 Million ≈ $133.13 Million |
-2.22% |
| 2023-12-31 | CN¥930.41 Million ≈ $136.15 Million |
-2.86% |
| 2022-12-31 | CN¥957.76 Million ≈ $140.15 Million |
+2.72% |
| 2021-12-31 | CN¥932.40 Million ≈ $136.44 Million |
+4.67% |
| 2020-12-31 | CN¥890.79 Million ≈ $130.35 Million |
+3.44% |
| 2019-12-31 | CN¥861.13 Million ≈ $126.01 Million |
+4.70% |
| 2018-12-31 | CN¥822.50 Million ≈ $120.36 Million |
+6.12% |
| 2017-12-31 | CN¥775.05 Million ≈ $113.41 Million |
+10.57% |
| 2016-12-31 | CN¥700.95 Million ≈ $102.57 Million |
+93.17% |
| 2015-12-31 | CN¥362.87 Million ≈ $53.10 Million |
+19.72% |
| 2014-12-31 | CN¥303.10 Million ≈ $44.35 Million |
+23.08% |
| 2013-12-31 | CN¥246.26 Million ≈ $36.04 Million |
+13.25% |
| 2012-12-31 | CN¥217.44 Million ≈ $31.82 Million |
-0.87% |
| 2011-12-31 | CN¥219.35 Million ≈ $32.10 Million |
-- |
About Zhejiang Xinguang Pharmaceutical Co Ltd
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquar… Read more